Alamar Biosciences (ALMR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.20
- Estimate
- -$0.32
- Surprise
- +37.4%
- Revenue (period 2026-06-30)
- $29.4M
- Score at report (before → after)
- 5.4 → 5.4/10
Revenue source: xbrl.
How the report landed
Alamar Biosciences (ALMR) reported a narrower loss than forecast — adjusted EPS of -$0.20 against the -$0.32 estimate (a 37.4% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALMR Sell at 5.7/10.
1 of the last 2 quarters beat the estimate; this quarter's +37.4% surprise compares with a +17.9% four-quarter average. Next scheduled report: 2027-02-18.
What supports the rating
- Sector modifier (Healthcare): +0.8
- Strong growth profile
What argues against it
- Negative momentum
- Value-trap signals (2/5): Margin compression (op margin -42.1%), Material insider selling (116 sells, 2.32% of cap)
- Momentum score 2.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.48
- Price target
- $32.19
- Stop
- $24.63
- Upside to target
- +21.6%
- Reward-to-risk
- 1.4:1
Model outputs from TrendMatrix’s engine as of 2026-11-22 — shown for context, not personalized investment advice.
ALMR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.84B
- P/E (fwd)
- -35.4
- 52-week range
- $18.85–$39.61
- Off 52-week high
- 33.1%
- RSI (14)
- 42
- Volume vs avg
- 1.00×
- Score today
- 5.7/10